Study investigator David Berg explains why volume overload shouldn't decide which hospitalized patients get an SGLT2 inhibitor.
|Videos|November 17, 2016
Medicare Home Infusion Site of Care Act and Specialty Pharmacy
Author(s)Lauren Santye, Assistant Editor
Wayne Grau, vice president of Legislative Affairs at Managed Health Care Associates, discusses the implications of the Medicare Home Infusion Site of Care Act for specialty pharmacy stakeholders.
Advertisement
Wayne Grau, vice president of Legislative Affairs at Managed Health Care Associates, discusses the implications of the Medicare Home Infusion Site of Care Act for specialty pharmacy stakeholders.
Advertisement
Related to this article
With changes in Medicaid eligibility looming, hospitals must plan now to keep patient care gaps at bay.
Apitegromab-mstn is cleared as an add-on to SMN2-targeted treatment for patients aged 2 and older, directly addressing muscle loss.
Once-daily oral deucrictibant extended-release significantly reduced hereditary angioedema attacks compared with placebo in the pivotal phase 3 CHAPTER-3 trial.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
FDA Approves Rebisufligene Etisparvovec as First Gene Therapy for Children With Sanfilippo Syndrome Type A
3
Radioligand Therapy Doesn’t Need to Be Risk-Free—It Needs to Be Worth It
4
FDA Reduces Monitoring Time for First Two Tarlatamab Doses
5